MRI for Dementia and Alzheimer's

What Is Dementia?

Dementia is not a single disease — it's an umbrella term for a group of conditions characterised by progressive decline in cognitive function severe enough to interfere with daily life. Memory loss is the most recognised symptom, but dementia also affects language, problem-solving, attention, and personality.

Alzheimer's disease is the most common type, accounting for 60-70% of cases. Vascular dementia (caused by reduced blood flow to the brain) is the second most common, followed by dementia with Lewy bodies and frontotemporal dementia. Mixed dementia — having more than one type simultaneously — is increasingly recognised, particularly in older adults.

Around 944,000 people in the UK are living with dementia, with numbers projected to exceed 1.6 million by 2040. One in three people born today will develop dementia in their lifetime. It's the UK's leading cause of death, overtaking heart disease in 2015.

Why MRI Is Used in Dementia Assessment

MRI is recommended by NICE as part of the standard diagnostic workup for suspected dementia. Its roles include:

• Ruling out other causes: Before attributing cognitive decline to a neurodegenerative condition, MRI excludes treatable causes — brain tumours, subdural haematoma (a blood collection from a fall), normal pressure hydrocephalus (NPH), and infections. These "reversible dementias" are uncommon but missing them is a serious error.
• Supporting the specific diagnosis: Different types of dementia produce characteristic patterns of brain atrophy visible on MRI. This helps distinguish Alzheimer's from frontotemporal dementia, vascular dementia, and other subtypes.
• Assessing vascular contribution: MRI shows white matter hyperintensities, old infarcts, and microbleeds — all evidence of cerebrovascular disease that may be contributing to cognitive decline.
• Baseline for monitoring: An initial MRI provides a reference point for tracking disease progression on follow-up scans.
• Research and clinical trials: Volumetric MRI (measuring brain volumes precisely) is used in clinical trials to assess whether treatments slow brain atrophy.

MRI Sequences Used

• T1-weighted volumetric (3D T1): The cornerstone sequence. Provides detailed brain anatomy with excellent grey-white matter contrast. Used to assess atrophy patterns — hippocampal volume, cortical thickness, ventricular size. Can be processed with automated volumetry software (NeuroQuant, FreeSurfer) to compare individual brain volumes against age-matched norms.
• FLAIR: Shows white matter hyperintensities (areas of bright signal in the brain's white matter) that indicate small vessel disease. The extent and distribution of these changes help assess vascular contribution to dementia.
• T2-weighted: Complements FLAIR for assessing overall brain structure, fluid spaces, and established pathology.
• SWI (Susceptibility-Weighted Imaging): Detects cerebral microbleeds. Their number, size, and distribution can help distinguish: lobar microbleeds suggesting cerebral amyloid angiopathy (associated with Alzheimer's) vs. deep/infratentorial microbleeds suggesting hypertensive vasculopathy.
• DWI: Important for detecting acute ischaemic events and for diagnosing Creutzfeldt-Jakob disease (CJD), which shows characteristic cortical and basal ganglia restricted diffusion.
• Coronal oblique T1 or T2 through the hippocampi: Thin-slice images angled perpendicular to the long axis of the hippocampus, optimised for assessing hippocampal atrophy — the hallmark of early Alzheimer's disease.

What Radiologists Look For

• Medial temporal lobe atrophy (MTA): Graded on the Scheltens scale (0-4). The hippocampus and surrounding structures (entorhinal cortex, parahippocampal gyrus) are the earliest brain regions affected in Alzheimer's. A score of 2 or more in someone under 75, or 3 or more in someone over 75, is considered abnormal.
• Global cortical atrophy (GCA): Graded 0-3. Assesses the width of sulci (brain grooves) and the degree of cortical thinning across the whole brain.
• Posterior atrophy (Koedam scale): Atrophy of the parietal and posterior cortex, which is prominent in posterior cortical atrophy (a variant of Alzheimer's) and sometimes in Lewy body dementia.
• Frontal and temporal lobe atrophy: Asymmetric frontal and/or anterior temporal atrophy is the hallmark of frontotemporal dementia. The pattern helps distinguish behavioural variant (frontal) from semantic (temporal) subtypes.
• White matter hyperintensity burden: Graded using the Fazekas scale (0-3). Extensive white matter changes suggest vascular contribution to cognitive decline.
• Strategic infarcts: Small infarcts in critical locations (thalamus, angular gyrus, caudate, hippocampus) can cause cognitive impairment disproportionate to their size.
• Normal pressure hydrocephalus features: Ventriculomegaly (enlarged ventricles) out of proportion to the degree of cortical atrophy, with periventricular flow voids. NPH is potentially treatable with a shunt.
• Space-occupying lesions: Tumours (especially frontal meningiomas) can present with personality change and cognitive decline mimicking dementia.

How to Prepare for the Scan

• Eat and drink normally. Continue all regular medications.
• If the person with suspected dementia is anxious or confused, a familiar family member or carer can accompany them to the scanning room (after their own metal safety screening) and sit with them during the scan in some centres.
• Remove hearing aids, glasses, dentures with metal, hairpins, and all jewellery.
• If the person has difficulty lying still or is very anxious, discuss this when booking. Some centres can offer mild sedation, though this needs advance planning.
• Bring a list of current medications and relevant medical history, particularly if the person being scanned may have difficulty recalling this information.

What Happens During the Scan

The person lies on their back with their head in a coil. The scan takes 25-40 minutes depending on the protocol. The volumetric T1 sequence (used for atrophy assessment) typically runs for 5-7 minutes as a single block.

Keeping still is important for image quality, but modern scanners can accommodate some minor movement. If the person is restless, the radiographer may need to repeat individual sequences rather than the entire scan.

Gadolinium contrast is not routinely used in dementia assessment. It may be added if the initial sequences raise suspicion of a tumour, infection, or inflammatory condition.

The scan is painless and non-invasive. The loudest sequences are the structural T1 and FLAIR. Earplugs and headphones are provided.

What MRI Can't Show

• Amyloid and tau pathology directly: The protein deposits that define Alzheimer's at a microscopic level (amyloid plaques and neurofibrillary tangles) are not visible on standard MRI. Amyloid PET scanning and CSF biomarkers can detect these, and blood-based biomarkers are emerging.
• Early-stage disease with certainty: In the earliest stages, brain volumes may still fall within the normal range. A normal MRI does not exclude early dementia — it needs to be interpreted alongside cognitive testing, clinical history, and sometimes biomarkers.
• Functional impact: MRI shows structural brain changes but doesn't directly measure how these affect a person's daily function. Neuropsychological testing fills this gap.
• Definitive differential diagnosis in all cases: Alzheimer's and Lewy body dementia can look very similar on MRI. Mixed dementias overlap in their imaging features. MRI supports the diagnosis but rarely makes it in isolation.
• Rate of future decline: While more severe atrophy generally correlates with more advanced disease, the rate of future cognitive decline varies enormously between individuals and can't be reliably predicted from a single scan.

Treatment Pathways After Diagnosis

• Cholinesterase inhibitors: Donepezil, rivastigmine, and galantamine are prescribed for mild-to-moderate Alzheimer's disease. They don't cure the disease but can help maintain cognitive function and daily living skills for a period.
• Memantine: Used for moderate-to-severe Alzheimer's. Can be combined with cholinesterase inhibitors.
• Vascular risk factor management: Aggressively treating hypertension, diabetes, high cholesterol, and stopping smoking can slow progression, particularly in vascular and mixed dementias.
• Anti-amyloid therapies: Lecanemab and donanemab are monoclonal antibodies that clear amyloid plaques. They're available in some countries for early Alzheimer's and may become available in the UK pending NICE appraisal. They require regular MRI monitoring for side effects (ARIA — amyloid-related imaging abnormalities).
• Non-pharmacological interventions: Cognitive stimulation therapy (recommended by NICE), physical exercise, social engagement, occupational therapy, and speech and language therapy all contribute to maintaining quality of life.
• Normal pressure hydrocephalus: If MRI suggests NPH, referral to neurosurgery for CSF drainage trial and potential ventriculoperitoneal shunt — one of the few truly treatable causes of dementia-like symptoms.
• Advance care planning: Early diagnosis provides an opportunity for the person and their family to plan ahead while they still have capacity to make decisions about future care.

Related Articles

• MRI for Stroke: What It Shows
• MRI for Brain Aneurysm Detection